PPT-Hemophilia March 11, 2016

By NamY7 Hemophilia was first recognized by the Jews but not officially named even in the ancient times In the 2 nd century AD the Talmud a Jewish collection of Rabbinical writings said that the boys did not have to be circumcised if two brothers died of the disease In 1800s it became known as the Royal Disease because many people of royal families died or got the disease Queen Victoria got Hemophilia but she survived Alexei the heir apparent to the Russian royal family suffered from Hemophilia In 1950s the first treatment to hemophilia appeared It was in a type called fresh frozen plasma Nowadays we are marching towards a cure but there are two treatments One is called gene therapy and the other is called Recombinant therapy A treatment for hemophilia is replacing old blood clots with new ones. 1. Expanding Therapeutic Options . for Hemophilia A and B: . Results of Recent Clinical Trials . Holleh D. Husseinzadeh, MD . Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. A REPORT FROM THE 65. February 4. th. , 2011. The Child With Pain. Single Joint Involvement. Multiple Joint Involvement. With Fever. Septic arthritis/Osteomyelitis. Sympathetic arthritis. Foreign body with infection. Traumatic arthritis. organization that assists and advocates for the bleeding disorders community.. MISSION. [Your Name]. [Date]. First Responders . &. von . Willebrand. Disease. © 2015 Hemophilia Federation of America. All rights reserved.. Recognition and Management of Patients with Hemophilia/von . Willebrand. Disease and Platelet Disorders. Rebecca Schaffer, DDS. Assistant Professor, Special Needs Care Unit. Associate Administrative Director, AEGD. Chemical Basis for Catalytic Activity. Enzymes promote . transition state. (. TS. ).. Transition state favored by tight binding. .. Figure depicts anti-CCR-5 “protease”.. Strategy. : Raise against TS analogs.. More Than Factor Replacement Prescription. IDG. . Ugrasena. Hematology-oncology division . Child Health . Departement. of Dr. . Soetomo. Hospital - Faculty of Medicine . Airlangga. University. Gen D. Introduction/Overview. Introduction/Overview (cont). Importance of Prophylaxis, and Limitations on Its Application, in Hemophilia B. Key Unmet Need in Hemophilia B:. Reducing Patient Burden of Disease. Sex-linked inheritance; almost all patients male. Female carriers may have mild symptoms. Most bleeding into joints, muscles; mucosal and CNS bleeding uncommon. Severity inversely proportional to factor level. WVNHF. Amber Tichnell, Executive Director. Hemophilia and other bleeding disorders. The human body is made up of several clotting factors – Factors 1 through 13 plus Von . Willebrand. Factor. A person can have deficiencies in any of these factors. Andrew J. . Costandi. , MD, MMM . Children’s Hospital Los Angeles. USC Keck School of Medicine. Faculty Disclosures. None. Learning Objectives. Upon completion of this activity, participants will be able to:. Veena Choubey, Rena Malik, and Luis Carlos Zapata Genetics Hemophilia is an X-linked recessive disorder that exists in two forms, hemophilia A and hemophilia B. Hemophilia A is characterized specif . Chelsea Marion, MD. 1,4. , Oluwaseun Odewole, MD, MPH. 2,4. , Sheila Goel, MD. 3,4. . 1. Dept. of Pediatrics, Morehouse School of Medicine, Atlanta, GA. . 2. Dept. of Family Medicine, Morehouse School of Medicine, Atlanta, GA. . Robin Reid, MD. Clinical Director, Mary M Gooley Hemophilia Center. Hematologist and Medical Oncologist, Rochester Regional Health. July . 2021. Outline. History of the Mary M Gooley Hemophilia Treatment Center. Lizheng Shi, PhD, . MsPharm. Regents Professor and Interim Chair. Department of Health policy and Management. School of Public Health and Tropical Medicine. Funded by BioMarin Pharmaceutical, which provided input into study design..